Positive Outcomes in Initial Immutep reports

Immutep Limited (ASX: IMM) reports positive outcomes from Cohort B of the TACTI-003 Phase IIb trial, where the combination of eftilagimod alfa and KEYTRUDA showed a 35.5% response rate in head and neck cancer patients. This combination demonstrated high efficacy, including a 58.1% disease control rate and a 9.7% complete response rate, surpassing historical controls for anti-PD-1 monotherapy. Notably, a patient initially showing progressive disease transitioned to a partial responder after 14 months. The safety profile remained favorable, with discussions on the way forward with regulatory agencies due to significant potential and unmet medical needs.

Immutep seeks regulatory discussions due to positive results and unmet medical needs, with Efti receiving FDA Fast Track designation for 1L HNSCC. A forthcoming webcast will offer investors more insights and the opportunity to pose questions in advance.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com